Video

Regular Screening Is Key for Hepatitis C

Author(s):

"One of the big problems we're having right now is trying to identify these patients with hepatitis C," Rick Davis, PA-C, University of Florida College of Medicine told MD Magazine. "We've found that the birth cohort of baby boomers (1945-1965) has the highest prevalence of infection, and now we're starting to see the results of that."

“One of the big problems we’re having right now is trying to identify these patients with hepatitis C,” Rick Davis, PA-C, University of Florida College of Medicine told MD Magazine. “We’ve found that the birth cohort of baby boomers (1945-1965) has the highest prevalence of infection, and now we’re starting to see the results of that.”

Davis explained that in patients that have chronic infection for 20-30 years, over 75% will go on to develop cirrhosis. This is where most of the complications occur with hepatitis C: increased risk of liver cancer, decompensation of liver disease, hospitalization, and unfortunately death.

He said that although there are good therapies that exist with very few side effects, Davis and team hope to get the primary care audience to identify more of these patients. “Even though these guidelines have been out for maybe 3 years or so, we’re still not getting the numbers screened that we should as part of patients’ regular screening care as you would for a mammogram or colon cancer screening.”

Davis explained that although the simple blood test for screening hepatitis C patients had initially experienced pushback, there are now ICD10 codes for this that can be used.

Interestingly, he pointed out that in the past providers used to ask whether patients had risk factors and ever used IV drugs, but “most people are not going to own up to whatever they did in the 70s or 60s now, they may be the Mayor of their towns or professional folks — that’s in their distant past. So, we don’t really care about that.”

Davis did stress there may be other risk factors in that birth cohort and that all they aim to do is identify the patients were born between 1945-1965 and reassure them they deserve a one-time blood test. “If it’s positive, then they need to have a confirmatory blood test to see do they have the infection now or have they cleared it and then linkage to care for treatment.”

Related Videos
Ben Samelson-Jones,Ben Samelson-Jones, MD, PhD: Validating Long-Term Safety of Hemophilia AAV Gene Therapy MD, PhD: Validating Long-Term Safety of Hemophilia AAV Gene Therapy
Françoise Bernaudin, MD: A Decade of Follow-up Reveals allo-SCT Superiority Over SOC for Sickle Cell Anemia
Achieving Quick Responses in Sickle Cell Anemia With Early, Appropriate Hydroxyurea Dosing, with Abena Appiah-Kubi, MD, MPH
Steven W. Pipe, MD: Fitusiran With Anti-Thrombin Modulation Yields Effective Bleed Control, Reduces Infusions
Caroline Piatek, MD: Improving Patient-Reported Outcomes in PNH With Danicopan Add-on Therapy
Haydar Frangoul, MD: Preventing VOCs in People With Sickle Cell Disease With Exa-Cel Gene Editing Therapy
Jörn Schattenberg, MD | Credit: Novo Nordisk
Jörn Schattenberg, MD | Credit: Novo Nordisk
Orrin Troum, MD: Accurately Imaging Gout With DECT Scanning
John Stone, MD, MPH: Continuing Progress With IgG4-Related Disease Research
© 2024 MJH Life Sciences

All rights reserved.